Clinical trials: Substrate Ablation
Persistent Atrial Fibrillation
AF Substrate Mapping and Guided Ablation
In this study, the investigators aim to identify and characterize, by means of an EnSite Velocity Research Software, the electrophysiological characteristics of substrates that sustain AF in patients with persistent AF and to…
- Trial name
- NCT02571218
- Testing
- Substrate+mCPVA, mCPVA
- Where
- Italy
- Volunteers
- 81 people
- Sponsor
- Abbott Medical Devices
Ventricular Tachycardia
FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study
This clinical investigation is intended to demonstrate the safety and effectiveness of ventricular ablation therapy using the FlexAbility Sensor Enabled Ablation Catheter in patients with drug-refractory monomorphic ventricular…
- Trial name
- LESS-VT (NCT03490201)
- Testing
- Market Approved RF Ablation System, FlexAbility SE Ablation Catheter
- Where
- 32 sites in United States, Australia and 6 more
- Volunteers
- 592 people
- Sponsor
- Abbott Medical Devices
Atrial Fibrillation
Use of Volta Medical AI-software During Atrial Fibrillation Ablation to Identify Patients Who May Need More Than Pulmonary Vein Isolation.
DISPLAY-AF is a prospective, multicenter, single-arm post-market clinical follow-up investigation designed to evaluate whether spatiotemporal dispersion areas identified by the Volta AF-Xplorer II artificial intelligence (AI)…
- Trial name
- DISPLAY-AF (NCT07807423)
- Testing
- Complete biatrial mapping
- Where
- 5 sites in France
- Volunteers
- 125 people
- Sponsor
- Volta Medical
Ventricular Tachycardia, Coronary Artery Disease
Substrate Modification in Stable Ventricular Tachycardia in Addition to Implantable Cardioverter Defibrillator (ICD) Therapy
The main objective of this study is to compare the time from randomization to the first recurrence of any ventricular tachycardia (VT) in patients undergoing VT ablation (for stable VTs) and substrate ablation (for unstable VTs)…
- Conditions
- Ventricular Tachycardia, Coronary Artery Disease, Left Ventricular Dysfunction
- Trial name
- VTACH (NCT00919373)
- Testing
- Substrate modification, VT ablation, ICD Implantation
- Where
- 16 sites in Czechia, Denmark and 2 more
- Volunteers
- 110 people
- Sponsor
- Abbott Medical Devices
Tachycardia, Ventricular
Comparison of VT Ablation Outcomes Using Remote MAGNETIC Navigation Versus Manual Approach in a Low LVEF Population
The study purpose is to demonstrate that ventricular tachycardia (VT) ablation using the Niobe™ ES system results in superior outcomes compared to a manual approach in subjects with ischemic scar VT in a low ejection fraction…
- Trial name
- MAGNETIC-VT (NCT02637947)
- Testing
- catheter ablation using magnetic navigation, catheter ablation using manual navigation
- Where
- 16 sites in United States, Australia and 5 more
- Volunteers
- 182 people
- Sponsor
- Stereotaxis
Atrial Fibrillation
STAR-AF:Substrate Versus Trigger Ablation for Reduction of Atrial Fibrillation Trial
Patient Population: Patients with AF that is symptomatic and refractory to at least one antiarrhythmic medication. Patients must have AF that is paroxysmal (>4 episodes within 6 months, two episodes >6 hours within 1 year) or…
- Trial name
- NCT00367757
- Testing
- Ablate AF triggers via PVI, Substrate via CFAEs, Combined approach for AF ablation
- Where
- 8 sites in Canada, Italy and 2 more
- Volunteers
- 107 people
- Sponsor
- Abbott Medical Devices
Monomorphic Ventricular Tachycardia
Substrate Targeted Ablation Using the FlexAbility™ Ablation Catheter System for the Reduction of Ventricular Tachycardia
To demonstrate that scar-based ventricular tachycardia (VT) ablation using the FlexAbility™ ablation catheter system results in a superior clinical outcome compared to routine drug therapy in subjects with documented Monomorphic…
- Trial name
- STAR-VT (NCT02130765)
- Testing
- Cardiac catheter ablation with ICD/CRT-D
- Where
- 38 sites in United States, Australia and 3 more
- Volunteers
- 64 people
- Sponsor
- Abbott Medical Devices
Atrial Fibrillation
Substrate and Trigger Ablation for Reduction of Atrial Fibrillation Trial - Star AF II Study
This investigation is designed with the hypothesis that combined PV Antral Isolation and Ablation of Complex Fractionated Electrograms (PVI+CFE) approach will offer a higher success rate compared to the Wide Circumferential…
- Trial name
- Star AF II (NCT01203748)
- Testing
- PVI + Lines ablation, PVI, PVI + CFE ablation
- Where
- 2 sites in Australia, Canada
- Volunteers
- 589 people
- Sponsor
- Abbott Medical Devices
Ischemic Ventricular Tachycardia
Dynamic Substrate Mapping (DSM) for Ischemic VT
This is a prospective, non-randomized study to determine the feasibility of using a new technique called Dynamic Substrate Mapping (DSM) to help guide the treatment of ischemic ventricular tachycardia (IVT).
- Trial name
- DSM (NCT00558857)
- Testing
- Dynamic Substrate Mapping-guided ablation
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Abbott Medical Devices
Atrial Arrhythmias
Pulmonary Vein Isolation Plus Left Atrial Slow Zone Mapping and Ablation
Pulmonary Vein Isolation Plus Left Atrial Slow Zone Mapping and Ablation: An AcQMap Substrate Characterization Study (PLASZMA)
- Trial name
- PLASZMA (NCT04512794)
- Testing
- AcQMap High Resolution Imaging and Mapping System
- Sponsor
- Acutus Medical